当前位置: 首页 >> 检索结果
6944. Iterative Reanalysis of Hypertrophic Cardiomyopathy Exome Data Reveals Causative Pathogenic Mitochondrial DNA Variants.
作者: Luis R Lopes.;David Murphy.;Enrico Bugiardini.;Reem Salem.;Joanna Jager.;Marta Futema.;Mohammed Majid Akhtar.;Konstantinos Savvatis.;Cathy Woodward.;Alan M Pittman.;Michael G Hanna.;Petros Syrris.;Robert D S Pitceathly.;Perry M Elliott.
来源: Circ Genom Precis Med. 2021年14卷3期e003388页 6945. Preterm Delivery and Long-Term Risk of Stroke in Women: A National Cohort and Cosibling Study.
Stroke has a high burden of disease in women, and adverse pregnancy outcomes have been identified as important risk factors for stroke later in life. However, long-term risks of stroke associated with preterm delivery and whether such risks are attributable to familial confounding are unclear. Such knowledge is needed to improve long-term risk assessment and stroke prevention in women.
6946. Cardiovascular Risk Factor Trajectories Since Childhood and Cognitive Performance in Midlife: The Cardiovascular Risk in Young Finns Study.
作者: Juuso O Hakala.;Katja Pahkala.;Markus Juonala.;Pia Salo.;Mika Kähönen.;Nina Hutri-Kähönen.;Terho Lehtimäki.;Tomi P Laitinen.;Eero Jokinen.;Leena Taittonen.;Päivi Tossavainen.;Jorma S A Viikari.;Olli T Raitakari.;Suvi P Rovio.
来源: Circulation. 2021年143卷20期1949-1961页
Cardiovascular risk factors, such as high blood pressure, adverse serum lipids, and elevated body mass index in midlife, may harm cognitive performance. It is important to note that longitudinal accumulation of cardiovascular risk factors since childhood may be associated with cognitive performance already since childhood, but the previous evidence is scarce. We studied the associations of cardiovascular risk factors from childhood to midlife, their accumulation, and midlife cognitive performance.
6947. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
作者: Kosuke Inoue.;Jose F Figueroa.;Colette DeJong.;Yusuke Tsugawa.;E John Orav.;Changyu Shen.;Dhruv S Kazi.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷5期e007521页
Marketing payments from the pharmaceutical industry to physicians have come under scrutiny due to their potential to influence clinical decision-making. Two proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were approved by the US Food and Drug Administration in 2015 for reducing low-density lipoprotein cholesterol in high-risk patients, but their initial uptake was limited due to their high-cost and stringent prior authorization requirements. We sought to investigate the association between industry marketing and early adoption of PCSK9i among US physicians.
6948. Variant Reinterpretation in Survivors of Cardiac Arrest With Preserved Ejection Fraction (the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry) by Clinicians and Clinical Commercial Laboratories.
作者: Brianna Davies.;Kirsten Bartels.;Julie Hathaway.;Fang Xu.;Jason D Roberts.;Rafik Tadros.;Martin S Green.;Jeffrey S Healey.;Christopher S Simpson.;Shubhayan Sanatani.;Christian Steinberg.;Martin Gardner.;Paul Angaran.;Mario Talajic.;Robert Hamilton.;Laura Arbour.;Colette Seifer.;Anne Fournier.;Jacqueline Joza.;Andrew D Krahn.;Anna Lehman.;Zachary W M Laksman.
来源: Circ Genom Precis Med. 2021年14卷3期e003235页
Following an unexplained cardiac arrest, clinical genetic testing is increasingly becoming standard of care. Periodic review of variant classification is required, as reinterpretation can change the diagnosis, prognosis, and management of patients and their relatives.
6949. Social Determinants of Adherence to COVID-19 Risk Mitigation Measures Among Adults With Cardiovascular Disease.
作者: Kobina K Hagan.;Zulqarnain Javed.;Miguel Cainzos-Achirica.;Dirk Sostman.;Farhaan S Vahidy.;Javier Valero-Elizondo.;Isaac Acquah.;Tamer Yahya.;Bita Kash.;Julia D Andrieni.;Prachi Dubey.;Adnan A Hyder.;Khurram Nasir.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷6期e008118页
Social determinants of health (SDOH) may limit the practice of coronavirus disease 2019 (COVID-19) risk mitigation guidelines with health implications for individuals with underlying cardiovascular disease (CVD). Population-based evidence of the association between SDOH and practicing such mitigation strategies in adults with CVD is lacking. We used the National Opinion Research Center's COVID-19 Household Impact Survey conducted between April and June 2020 to evaluate sociodemographic disparities in adherence to COVID-19 risk mitigation measures in a sample of respondents with underlying CVD representing 18 geographic areas of the United States.
6950. Response by Marquetand and Reil to Letter Regarding Article, "Invasive and Echocardiographic Characteristics of a Patient With Severe Pulmonary Valve Regurgitation Pretending Severe Pulmonary Stenosis".6952. Practice Patterns After Return of Rare Variants Associated With Cardiomyopathy in the Electronic Medical Records and Genomics Network.
作者: Sadiya S Khan.;Christin Hoell.;Lisa M Castillo.;John J Connolly.;David R Crosslin.;Wendy K Chung.;Adam S Gordon.;Margaret Harr.;Gail P Jarvik.;Iftikhar Kullo.;Eric B Larson.;Kathleen A Leppig.;Teri Manolio.;Jennifer A Pacheco.;James D Ralston.;Megan J Puckelwartz.;Maureen E Smith.;Quinn Wells.;Elizabeth M McNally.;Laura J Rasmussen-Torvik.
来源: Circ Heart Fail. 2021年14卷5期e008155页 6953. Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction.
作者: Claudia Baratto.;Sergio Caravita.;Davide Soranna.;Andrea Faini.;Céline Dewachter.;Antonella Zambon.;Giovanni Battista Perego.;Antoine Bondue.;Michele Senni.;Luigi P Badano.;Gianfranco Parati.;Jean-Luc Vachiéry.
来源: Circ Heart Fail. 2021年14卷5期e007555页
Exercise hemodynamics can differentiate heart failure with preserved ejection fraction (HFpEF) from noncardiac dyspnea. However, respiratory pressure swings may impact hemodynamic measurements, potentially leading to misdiagnosis of HFpEF. Moreover, threshold values for abnormal hemodynamic response indicative of HFpEF are not universally accepted. Thus, we sought to evaluate the impact of respiratory pressure swings on hemodynamic data interpretation as well as the concordance among 3 proposed exercise hemodynamic criteria for HFpEF: (1) end-expiratory pulmonary artery wedge pressure (PAWPexp) ≥25 mm Hg; (2) PAWPexp/cardiac output slope >2 mm Hg/L per minute; and (3) respiratory-averaged (avg) mean pulmonary artery pressure >30 mm Hg, total pulmonary resistanceavg >3 WU, PAWPavg ≥20 mm Hg.
6954. Bridging With Extracorporeal Membrane Oxygenation Under the New Heart Allocation System: A United Network for Organ Sharing Database Analysis.
作者: Taylor Nordan.;Andre C Critsinelis.;Shant H Mahrokhian.;Navin K Kapur.;Katherine L Thayer.;Frederick Y Chen.;Gregory S Couper.;Masashi Kawabori.
来源: Circ Heart Fail. 2021年14卷5期e007966页
The effect of the new donor heart allocation system on survival following bridging to transplantation with venous-arterial extracorporeal membrane oxygenation remains unknown. The new allocation system places extracorporeal membrane oxygenation-supported candidates at the highest status.
6955. Acute Myocarditis by Immune Checkpoint Inhibitor Identified by Quantitative Pixel-Wise Analysis of Native T1 Mapping.
作者: Shingo Kato.;Kazuki Fukui.;Sho Kodama.;Mai Azuma.;Naoki Nakayama.;Mayuko Kishimoto.;Tae Iwasawa.;Kazuo Kimura.;Kouichi Tamura.;Daisuke Utsunomiya.
来源: Circ Cardiovasc Imaging. 2021年14卷5期e012177页 6956. Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population.
作者: Kathleen A Young.;Christopher G Scott.;Richard J Rodeheffer.;Horng H Chen.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷5期e007216页
The aims of this study are to evaluate the rate of progression of preclinical (Stage A and B) heart failure, identify associated characteristics, and evaluate long-term outcomes.
6958. Ischemia From Nonculprit Stenoses Is Not Associated With Reduced Culprit Infarct Size in Patients with ST-Segment-Elevation Myocardial Infarction.
作者: Kathrine Ekström.;Julie V W Nielsen.;Lars Nepper-Christensen.;Kiril A Ahtarovski.;Kasper Kyhl.;Christoffer Göransson.;Litten Bertelsen.;Adam A Ghotbi.;Henning Kelbæk.;Dan E Høfsten.;Lars Køber.;Mikkel M Schoos.;Niels Vejlstrup.;Jacob Lønborg.;Thomas Engstrøm.
来源: Circ Cardiovasc Imaging. 2021年14卷5期e012290页
In patients with ST-segment-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention, reperfusion injury accounts for a significant fraction of the final infarct size, which is directly related to patient prognosis. In animal studies, brief periods of ischemia in noninfarct-related (nonculprit) coronary arteries protect the culprit myocardium via remote ischemic preconditioning. Positive fractional flow reserve (FFR) documents functional significant coronary nonculprit stenosis, which may offer remote ischemic preconditioning of the culprit myocardium. The aim of the study was to investigate the association between functional significant, multivessel disease (MVD) and reduced culprit final infarct size or increased myocardial salvage (myocardial salvage index [MSI]) in a large contemporary cohort of STEMI patients.
6959. Cyclin D2 Overexpression Enhances the Efficacy of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Myocardial Repair in a Swine Model of Myocardial Infarction.
作者: Meng Zhao.;Yuji Nakada.;Yuhua Wei.;Weihua Bian.;Yuxin Chu.;Anton V Borovjagin.;Min Xie.;Wuqiang Zhu.;Thanh Nguyen.;Yang Zhou.;Vahid Serpooshan.;Gregory P Walcott.;Jianyi Zhang.
来源: Circulation. 2021年144卷3期210-228页
Human induced pluripotent stem cells with normal (wild-type) or upregulated (overexpressed) levels of CCND2 (cyclin D2) expression were differentiated into cardiomyocytes (CCND2WTCMs or CCND2OECMs, respectively) and injected into infarcted pig hearts.
6960. Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire.
作者: Poghni A Peri-Okonny.;Jingyan Wang.;Kensey L Gosch.;Manesh R Patel.;Mehdi H Shishehbor.;David L Safley.;J Dawn Abbott.;Herbert D Aronow.;Carlos Mena-Hurtado.;Qurat-Ul-Ain Jelani.;Yuanyuan Tang.;Matthew Bunte.;Clementine Labrosciano.;John F Beltrame.;John A Spertus.;Kim G Smolderen.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷5期e007232页
Understanding minimum clinically important differences (MCID) in patient-reported outcomes is essential in interpreting the magnitude of changes in these measures. No MCID from patients' perspectives has ever been published for peripheral artery disease-specific health status assessment tools. The Peripheral Artery Questionnaire (PAQ) is a commonly used, validated peripheral artery disease-specific health status instrument for which we sought to prospectively establish its MCID from patients' perspectives.
|